Kamyar Kalantar
Nephrology · Orange, CANPI 1457314684
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.2%. Reporting peaked in 2022 at $147,432 and has fallen 77.6% since, to $32,972 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $1358.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius Kabi USA, LLC$52K
- Fresenius USA Marketing, Inc.$50K
- Vifor Pharma, Inc.$47K
- Daiichi Sankyo Inc.$36K
- GSK$23K
- AstraZeneca$20K
- plus $193K from 20 others
What the payments were for
- Consulting fees$213,62251%
- Speaking & faculty fees$152,94736%
- Travel & lodging$46,98011%
- Food & beverage$6,9622%
- Education$30%
- Gifts$4750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius Kabi USA, LLC | 16 | $51,554 |
| Fresenius USA Marketing, Inc. | 65 | $50,486 |
| Vifor Pharma, Inc. | 34 | $47,220 |
| Daiichi Sankyo Inc. | 26 | $35,795 |
| GSK | 6 | $23,014 |
| AstraZeneca | 24 | $20,315 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 9 | $18,434 |
| Akebia Therapeutics Inc | 12 | $18,091 |
| Nxstage Medical, Inc. | 22 | $16,686 |
| Calliditas Therapeutics US Inc. | 9 | $16,552 |
| Vifor (international) Ltd. | 5 | $14,553 |
| CSL Behring | 10 | $14,249 |
| American Regent | 2 | $13,877 |
| Novo Nordisk | 7 | $12,124 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $11,580 |
| Sanofi US Services Inc. | 5 | $10,675 |
| Amgen(2 entities) | 11 | $10,550 |
| Travere Therapeutics, Inc. | 9 | $9,420 |
| Hikma Pharmaceuticals USA | 2 | $6,000 |
| Pfizer | 2 | $4,810 |
| Novo Nordisk AS | 1 | $3,520 |
| Astrazeneca UK Limited | 3 | $3,156 |
| Scpharmaceuticals Inc. | 2 | $3,132 |
| Otsuka America Pharmaceutical, Inc. | 13 | $2,927 |
| Pharmacosmos Therapeutics Inc. | 2 | $2,166 |
| Sanofi Pasteur Inc. | 1 | $104 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Velphoro$53,923
- INJECTAFER$49,382
- NXSTAGE SYSTEM ONE$16,553
- TARPEYO$16,434
- LOKELMA$11,730
- AURYXIA$10,677
- KRYSTEXXA$10,306
- Veltassa$9,889
- Korsuva$6,523
- JYNARQUE$4,418
- FUROSCIX$3,132
- TOLVAPTAN$2,720
- Monoferric$2,140
- MD-Other$942
- SAMSCA$548
- FLUBLOK QUADRIVALENT$104
- FLUZONE HIGH-DOSE$104
How this compares
$420,989 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Orange
- Yasir QaziOrange$618K
- Ramy HannaOrange$446K
- Rebecca AhdootOrange$66K
- Yongen ChangOrange$48K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.